Loading patent…
AssigneeThe Institute for Ethnomedicine
InventorsPaul A Cox, Sandra A Banack, Susan Murch
Estimating the term…
Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.
A method of screening a human subject having or at risk of having Alzheimer's disease or amyotrophic lateral sclerosis-Parkinsonism dementia complex (ALS-PDC) comprising, analyzing a keratinous tissue sample from the subject to determine the presence of β-N-methylamino-L-alanine (BMAA), wherein the presence of BMAA in the sample indicates the subject has or is at risk of having Alzheimer's disease or ALS-PDC.
Dependencies are inferred from the claim text.